Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03649880 · ClinicalTrials.gov registry record · Phase 2
Feasibility of FMISO in Brain Tumors
A Phase 2 study of Malignant Brain Neoplasm, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03649880: Recruiting Phase 2 study of Malignant Brain Neoplasm, sponsored by OHSU Knight Cancer Institute.
NCT03649880 is a Phase 2 study of Malignant Brain Neoplasm that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 50 participants, below the 225-participant average among 12 other Malignant Brain Neoplasm trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03649880, a Phase 2 study of Malignant Brain Neoplasm, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Primary Outcome
Assessed as a factor of generating quantitative positron emission tomography (PET)/magnetic resonance imaging (MRI) metrics (intra-tumoral FMISO tumor to blood \[T/B\] level, hypoxic volume, dynamic susceptibility contrast enhanced \[DSC\], and diffusion-weighted imaging \[DWI\] values, and tissue oxygen maps). Images generated during the administration of oxygen will be used to generate tissue oxygen maps of the brain. Following completion of cohort enrollment, the generation of each quantitati
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- DRUG ¹⁸F-Fluoromisonidazole
- PROCEDURE Oxygen Therapy
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
What NCT03649880 shows while recruiting
NCT03649880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 225-participant average among 12 other Malignant Brain Neoplasm trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Malignant Brain Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT03649880 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03649880 about?
NCT03649880 is a clinical study titled "Feasibility of FMISO in Brain Tumors". This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how t...
What is the current status of trial NCT03649880?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2019-06-01. Estimated completion is 2030-01-31.
What conditions does trial NCT03649880 study?
This clinical trial studies the following conditions: Malignant Brain Neoplasm.
What interventions are being tested in trial NCT03649880?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), ¹⁸F-Fluoromisonidazole (DRUG), Oxygen Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT03649880?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03649880 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03649880's enrollment target sits among peer trials
50 6th of 12 higher than 6 of 12 other Malignant Brain Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Brain Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
RECRUITING · NA
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI